These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 17562848)

  • 1. Interferon-beta: mechanism of action and dosing issues.
    Markowitz CE
    Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
    Jensen J; Krakauer M; Sellebjerg F
    Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
    Graber J; Zhan M; Ford D; Kursch F; Francis G; Bever C; Panitch H; Calabresi PA; Dhib-Jalbut S
    J Neuroimmunol; 2005 Apr; 161(1-2):169-76. PubMed ID: 15748956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
    Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
    J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
    Bernal F; Elias B; Hartung HP; Kieseier BC
    Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients.
    Sternberg Z; Chadha K; Lieberman A; Hojnacki D; Drake A; Zamboni P; Rocco P; Grazioli E; Weinstock-Guttman B; Munschauer F
    J Neuroimmunol; 2008 Dec; 205(1-2):142-7. PubMed ID: 18926575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.